The Experts below are selected from a list of 207 Experts worldwide ranked by ideXlab platform
Ediléia Bagatin - One of the best experts on this subject based on the ideXlab platform.
-
Cutaneous fungal microbiome: Malassezia yeasts in seborrheic dermatitis scalp in a randomized, comparative and therapeutic trial
Dermato-endocrinology, 2017Co-Authors: Cristhine Souza Leão Kamamoto, Karime Marques Hassun, Angela Satie Nishikaku, Olga Fischman Gompertz, Analy Salles De Azevedo Melo, Ediléia BagatinAbstract:Malassezia spp in skin microbiome scalp has been implicated in seborrheic dermatitis pathogenesis. Thus, treatment based in antifungal combined to topical keratolitic agents have been indicated as well as oral isotretinoin as it reduces the sebum production, glandular's size and possesses anti-inflammatory properties. This randomized, comparative and therapeutic trial aimed toper form the genotypic identification of Malassezia species before and after low-dose oral isotretinoin or topical antifungal treatments for moderate to severe Seborrhea and/or seborrheic dermatitis on scalp. Scales and sebum of the scalp were seeded in the middle of modified Dixon and incubated at 32°C. For genotypic identification polymerase chain reaction primers for the ITS and D1/D2 ribossomal DNA were used and followed by samples sequencing. The procedure was conducted before and after therapeutic and randomized intervention for moderate to severe Seborrhea/seborrheic dermatitis on the scalp, including oral isotretinoin, 10 mg, every other day and anti-seborrheic shampoo (piroctone olamine), over six months. The M. globosa and M. restricta were the most frequent species isolated on the scalp before and after both treatments. Other non-Malassezia species were also identified. The Malassezia spp. were maintained in the scalp after both treatments that were equally effective for the control of Seborrhea/seborrheic dermatitis clinical signs.
-
Low-dose oral isotretinoin for moderate to severe Seborrhea and seborrheic dermatitis: a randomized comparative trial
International journal of dermatology, 2016Co-Authors: Cristhine Souza Leão Kamamoto, Adriana Sañudo, Karime Marques Hassun, Ediléia BagatinAbstract:Background The efficacy of low-dose oral isotretinoin in the treatment of Seborrhea and seborrheic dermatitis has been poorly investigated in randomized studies. Objectives This study was designed to determine the efficacy and safety of low-dose oral isotretinoin in the treatment of moderate to severe Seborrhea and seborrheic dermatitis on the scalp and/or face. Methods A randomized, comparative clinical trial, using two groups, was conducted over 6 months. Patients in Group ISO were treated with isotretinoin 10 mg every other day. In Group X, patients received antiseborrheic topical treatment. Patient opinion, investigator assessment, scalp pruritus, sebum production, and quality of life (QoL) comprised the efficacy outcomes. Results The intention-to-treat population comprised a total of 45 patients with mean ± standard deviation ages of 28.7 ± 5.8 years in Group ISO and 29.8 ± 6.5 years in Group X. The rate of sebum production significantly decreased in Group ISO. Patient opinion, investigator, and QoL assessments improved in both groups. Conclusions Low-dose oral isotretinoin can be a therapeutic modality for moderate to severe Seborrhea and seborrheic dermatitis.
O.n. Golubeva - One of the best experts on this subject based on the ideXlab platform.
-
Effects of a phasic oral contraceptive containing desogestrel on facial Seborrhea and acne
Contraception, 2003Co-Authors: Vera N Prilepskaya, V.n. Serov, E.v. Zharov, I.j. Golousenko, E.a. Mejevitinova, E.v. Gogaeva, V.v. Yaglov, O.n. GolubevaAbstract:Abstract Background The combined oral contraceptive containing ethinylestradiol and the selective progestogen, desogestrel, in a phasic regimen (DSG-OC, Tri-merci®) has been shown to reduce facial oiliness. Objective This study was designed to evaluate further the effects of this OC on the skin of women with facial Seborrhea and mild or moderate acne. Design and methods This was an open, noncomparative, bicenter study in 60 healthy Russian women, aged 18–30 years, with facial Seborrhea and mild or moderate facial acne, who wished to use oral contraception. All women received the OC containing desogestrel (50/100/150 μg) and ethinylestradiol (35/30/30 μg) for three phases of 7 days followed by a 7-day pill-free interval, for six cycles. Seborrhea was assessed using the Sebutape® technique, in which strips of adhesive microporous polymeric film pressed onto facial sites are used to assess sebaceous activity. Acne was assessed by counting facial lesions. Subjective evaluations of skin and hair condition, patients' feelings to them and satisfaction with the OC were made using a visual analogue scale (VAS). Assessments were made at baseline, and after one, three and six treatment cycles. Results Sebutape assessments of Seborrhea were significantly improved, on the right and left cheeks, after one treatment cycle, and on the forehead after three treatment cycles. These improvements increased steadily and were much larger at the end of Cycle 6. Acne grades were significantly improved after three and six treatment cycles. VAS scores in response to questions dealing with self-esteem and self-confidence were significantly improved after three cycles and in some cases after just one cycle. The women's views of their skin and hair (greasiness) were correspondingly significantly improved. Subjective assessments indicated that after one, three and six cycles, 69%, 93% and 98%, respectively, of women were satisfied or very satisfied with the DSG-OC. Conclusion In women with facial Seborrhea and mild or moderate acne, the use of DSG-OC appears to improve Seborrhea after just one cycle and acne grades after three cycles. These improvements are accompanied by increases in self-esteem and confidence.
Cristhine Souza Leão Kamamoto - One of the best experts on this subject based on the ideXlab platform.
-
Cutaneous fungal microbiome: Malassezia yeasts in seborrheic dermatitis scalp in a randomized, comparative and therapeutic trial
Dermato-endocrinology, 2017Co-Authors: Cristhine Souza Leão Kamamoto, Karime Marques Hassun, Angela Satie Nishikaku, Olga Fischman Gompertz, Analy Salles De Azevedo Melo, Ediléia BagatinAbstract:Malassezia spp in skin microbiome scalp has been implicated in seborrheic dermatitis pathogenesis. Thus, treatment based in antifungal combined to topical keratolitic agents have been indicated as well as oral isotretinoin as it reduces the sebum production, glandular's size and possesses anti-inflammatory properties. This randomized, comparative and therapeutic trial aimed toper form the genotypic identification of Malassezia species before and after low-dose oral isotretinoin or topical antifungal treatments for moderate to severe Seborrhea and/or seborrheic dermatitis on scalp. Scales and sebum of the scalp were seeded in the middle of modified Dixon and incubated at 32°C. For genotypic identification polymerase chain reaction primers for the ITS and D1/D2 ribossomal DNA were used and followed by samples sequencing. The procedure was conducted before and after therapeutic and randomized intervention for moderate to severe Seborrhea/seborrheic dermatitis on the scalp, including oral isotretinoin, 10 mg, every other day and anti-seborrheic shampoo (piroctone olamine), over six months. The M. globosa and M. restricta were the most frequent species isolated on the scalp before and after both treatments. Other non-Malassezia species were also identified. The Malassezia spp. were maintained in the scalp after both treatments that were equally effective for the control of Seborrhea/seborrheic dermatitis clinical signs.
-
Low-dose oral isotretinoin for moderate to severe Seborrhea and seborrheic dermatitis: a randomized comparative trial
International journal of dermatology, 2016Co-Authors: Cristhine Souza Leão Kamamoto, Adriana Sañudo, Karime Marques Hassun, Ediléia BagatinAbstract:Background The efficacy of low-dose oral isotretinoin in the treatment of Seborrhea and seborrheic dermatitis has been poorly investigated in randomized studies. Objectives This study was designed to determine the efficacy and safety of low-dose oral isotretinoin in the treatment of moderate to severe Seborrhea and seborrheic dermatitis on the scalp and/or face. Methods A randomized, comparative clinical trial, using two groups, was conducted over 6 months. Patients in Group ISO were treated with isotretinoin 10 mg every other day. In Group X, patients received antiseborrheic topical treatment. Patient opinion, investigator assessment, scalp pruritus, sebum production, and quality of life (QoL) comprised the efficacy outcomes. Results The intention-to-treat population comprised a total of 45 patients with mean ± standard deviation ages of 28.7 ± 5.8 years in Group ISO and 29.8 ± 6.5 years in Group X. The rate of sebum production significantly decreased in Group ISO. Patient opinion, investigator, and QoL assessments improved in both groups. Conclusions Low-dose oral isotretinoin can be a therapeutic modality for moderate to severe Seborrhea and seborrheic dermatitis.
Julia R. Nunley - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of seborrheic dermatitis.
American family physician, 2000Co-Authors: Betty Anne Johnson, Julia R. NunleyAbstract:Seborrheic dermatitis is a chronic inflammatory disorder affecting areas of the head and trunk where sebaceous glands are most prominent. Lipophilic yeasts of the Malassezia genus, as well as genetic, environmental and general health factors, contribute to this disorder. Scalp Seborrhea varies from mild dandruff to dense, diffuse, adherent scale. Facial and trunk Seborrhea is characterized by powdery or greasy scale in skin folds and along hair margins. Treatment options include application of selenium sulfide, pyrithione zinc or ketoconazole-containing shampoos, topical ketoconazole cream or terbinafine solution, topical sodium sulfacetamide and topical corticosteroids.
Gerd Plewig - One of the best experts on this subject based on the ideXlab platform.
-
Pathophysiologie der Akne
Der Hautarzt; Zeitschrift fur Dermatologie Venerologie und verwandte Gebiete, 2005Co-Authors: Claudia Borelli, Gerd Plewig, Klaus DegitzAbstract:Several pathogenic factors contribute to the development of acne, among them, Seborrhea, follicular hyperkeratosis, propionibacteria, and inflammatory events. This article reviews current knowledge of these pathogenic factors.
-
Very low dose isotretinoin is effective in controlling Seborrhea.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2003Co-Authors: Sabine E. Geißler, Silke Michelsen, Gerd PlewigAbstract:Summary Background: Excessive Seborrhea, coarse-pored skin, minimal acne and oily scalp hair comprise a well-known clinical entity. It causes considerable concern, has social impact, and affects the quality of life in some individuals. Some patients seek treatment for Seborrhea. No effective topical sebosuppressive medication is available. Oral isotretinoin is the only remedy for men. In women, oral isotretinoin is the most effective remedy, followed by antiandrogens. Patients and methods: Eleven patients in three groups were treated for 6 months with very low dose isotretinoin. The influence on Seborrhea was measured during oral treatment with 5 mg/d, 2.5 mg/d, or 2.5 mg 3× weekly. Results: Sebum production, measured with Sebutape®, was reduced by up to 64 %. Acne lesions regressed by as much as 84 %. Follicular filaments were reduced by 66 %. Microcomedones were reduced on average up to 86 %. Quantitative bacteriology showed a reduction of Propionibacterium acnes but no increase of Staphylococcus epidermidis. Biopsies revealed a 51 % reduction in sebaceous gland size. With Bentonite™, a reduction of lipids was demonstrated with 2.5 and 5 mg isotretinoin/d but not with 2.5 mg 3× weekly. There was a shift within the lipid fractions: triglycerides dominated, followed by squalenes and free fatty acids. Conclusions: Good results were achieved in all patients. The small number of patients did not permit a statistical analysis of the three isotretinoin doses studied, but there was a tendency toward better results with the two higher doses.
-
Polycystic Ovary Syndrome and SAHA Syndrome
ACNE and ROSACEA, 2000Co-Authors: Gerd Plewig, Albert M. KligmanAbstract:The term SAHA syndrome (acronym for Seborrhea, acne, hirsutism, alopecia) comprises the most common manifestations of hyperandrogenism. In women, the most common cause of hyperandrogenism is polycystic ovary (PCO) syndrome.
-
diffuse sebaceous gland hyperplasia a case report and an immunohistochemical study with cytokeratins
American Journal of Dermatopathology, 1996Co-Authors: Carl Georg Schirren, T Jansen, Annegret Lindner, Peter Kind, Gerd PlewigAbstract:We report a 43-year-old woman with sebaceous gland hyperplasia that occurred in a diffuse pattern of aggregated papular lesions involving her entire face, neck, and upper chest. Comedones, pustules, and inflammatory papules were absent. The eruption was accompanied by marked Seborrhea. Histopatholog